Percheron Therapeutics Ltd (PER) - Total Liabilities
Based on the latest financial reports, Percheron Therapeutics Ltd (PER) has total liabilities worth AU$2.43 Million AUD (≈ $1.72 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Percheron Therapeutics Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Percheron Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Percheron Therapeutics Ltd to evaluate short-term liquidity relative to the company's equity base.
Percheron Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Percheron Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tiphone Mobile Indonesia Tbk
JK:TELE
|
Indonesia | Rp4.84 Trillion |
|
Western Gold Exploration Ltd
V:WGLD
|
Canada | CA$9.55K |
|
GSP Resource Corp
V:GSPR
|
Canada | CA$16.48K |
|
Young & Co’S Brewery A
LSE:YNGA
|
UK | GBX519.70 Million |
|
Mountain Province Diamonds Inc
TO:MPVD
|
Canada | CA$762.30 Million |
|
Li Bang International Corporation Inc. Ordinary Shares
NASDAQ:LBGJ
|
USA | $20.02 Million |
|
Lavide Holding NV
AS:LVIDE
|
Netherlands | €591.86K |
|
Arcadia Minerals Ltd
AU:AM7
|
Australia | AU$865.44K |
Liability Composition Analysis (2001–2025)
This chart breaks down Percheron Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Percheron Therapeutics Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Percheron Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Percheron Therapeutics Ltd (2001–2025)
The table below shows the annual total liabilities of Percheron Therapeutics Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$2.43 Million ≈ $1.72 Million |
-52.93% |
| 2024-06-30 | AU$5.17 Million ≈ $3.66 Million |
+80.21% |
| 2023-06-30 | AU$2.87 Million ≈ $2.03 Million |
+121.38% |
| 2022-06-30 | AU$1.30 Million ≈ $916.45K |
+1.74% |
| 2021-06-30 | AU$1.27 Million ≈ $900.78K |
+55.02% |
| 2020-06-30 | AU$821.23K ≈ $581.07K |
-7.61% |
| 2019-06-30 | AU$888.84K ≈ $628.91K |
+53.02% |
| 2018-06-30 | AU$580.86K ≈ $411.00K |
-15.28% |
| 2017-06-30 | AU$685.65K ≈ $485.14K |
-8.60% |
| 2016-06-30 | AU$750.20K ≈ $530.82K |
+29.03% |
| 2015-06-30 | AU$581.44K ≈ $411.41K |
+2.16% |
| 2014-06-30 | AU$569.13K ≈ $402.70K |
+2.71% |
| 2013-06-30 | AU$554.10K ≈ $392.06K |
+30.90% |
| 2012-06-30 | AU$423.29K ≈ $299.50K |
+1.33% |
| 2011-06-30 | AU$417.74K ≈ $295.58K |
-11.39% |
| 2010-06-30 | AU$471.43K ≈ $333.56K |
-55.60% |
| 2009-06-30 | AU$1.06 Million ≈ $751.24K |
-69.93% |
| 2008-06-30 | AU$3.53 Million ≈ $2.50 Million |
+73.73% |
| 2007-06-30 | AU$2.03 Million ≈ $1.44 Million |
+529.17% |
| 2006-06-30 | AU$323.03K ≈ $228.56K |
-9.70% |
| 2005-06-30 | AU$357.72K ≈ $253.11K |
-64.87% |
| 2004-06-30 | AU$1.02 Million ≈ $720.40K |
+179.40% |
| 2003-06-30 | AU$364.40K ≈ $257.84K |
-80.33% |
| 2002-06-30 | AU$1.85 Million ≈ $1.31 Million |
+3301.59% |
| 2001-06-30 | AU$54.46K ≈ $38.53K |
-- |
About Percheron Therapeutics Ltd
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more